Premium
A phase II study of recombinant human alpha‐interferon in advanced hormone‐refractory prostate cancer
Author(s) -
Van HaelstPisani Carol M.,
Richardson Ronald L.,
Su John,
Buckner Jan C.,
Hahn Richard G.,
Frytak Stephen,
Kvols Larry K.,
Burch Patrick A.
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19921101)70:9<2310::aid-cncr2820700916>3.0.co;2-4
Subject(s) - medicine , prostate cancer , refractory (planetary science) , prostate , cancer , toxicity , alpha (finance) , recombinant dna , oncology , disease , alpha interferon , gastroenterology , urology , surgery , interferon , immunology , construct validity , biochemistry , physics , chemistry , astrobiology , gene , patient satisfaction
Abstract To determine the efficacy of recombinant human leukocyte alpha‐interferon (IFL‐RA) in advanced hormone‐refractory prostate cancer, the authors treated 40 patients with IFL‐RA administered intramuscularly at a dose of 10 × 10 8 U/m 2 three times weekly. Toxicity was substantial and necessitated at least a 50% dose reduction in all but five patients during the first 1‐2 months of therapy. No responses were observed in patients with bone metastases, but complete and partial regression of nodal disease were observed in two patients with extraosseous disease (overall response rate, 5%; 95% confidence interval, 0.64‐17.75%). The authors conclude that IFL‐RA cannot be recommended at this dose and schedule in patients with advanced prostate cancer, but additional study of its use in patients with nodal disease may be warranted. Cancer 1992; 702310‐2312.